These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 37308951)

  • 21. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
    Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
    Akiyama MJ; Lipsey D; Ganova-Raeva L; Punkova LT; Agyemang L; Sue A; Ramachandran S; Khudyakov Y; Litwin AH
    J Infect Dis; 2020 Jul; 222(3):488-498. PubMed ID: 32150621
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis C Reinfection in People Who Inject Drugs in Resource-Limited Countries: A Systematic Review and Analysis.
    Muller A; Vlahov D; Akiyama MJ; Kurth A
    Int J Environ Res Public Health; 2020 Jul; 17(14):. PubMed ID: 32659974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.
    Valerio H; Alavi M; Conway A; Silk D; Treloar C; Martinello M; Milat A; Dunlop A; Murray C; Henderson C; Amin J; Read P; Marks P; Degenhardt L; Stevens A; Prain B; Hayllar J; Reid D; Montebello M; Wade A; Christmass M; Cock V; Dore GJ; Grebely J;
    Int J Drug Policy; 2022 Jul; 105():103706. PubMed ID: 35533635
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Public health interventions, priority populations, and the impact of COVID-19 disruptions on hepatitis C elimination among people who have injected drugs in Montreal (Canada): A modeling study.
    Lanièce Delaunay C; Klein MB; Godin A; Cox J; Kronfli N; Lebouché B; Doyle C; Maheu-Giroux M
    Int J Drug Policy; 2023 Jun; 116():104026. PubMed ID: 37075626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial.
    Litwin AH; Lum PJ; Taylor LE; Mehta SH; Tsui JI; Feinberg J; Kim AY; Norton BL; Heo M; Arnsten J; Meissner P; Karasz A; Mckee MD; Ward JW; Johnson N; Pericot-Valverde I; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Roche J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Page K;
    Lancet Gastroenterol Hepatol; 2022 Dec; 7(12):1112-1127. PubMed ID: 36370741
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hepatitis C reinfection by treatment pathway among people who inject drugs in Tayside, Scotland.
    Caven M; Baiano CX; Robinson EM; Stephens B; Macpherson I; Dillon JF
    J Viral Hepat; 2021 Dec; 28(12):1744-1750. PubMed ID: 34525228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study.
    Grebely J; Gilliver R; McNaughton T; Conway A; Cunningham E; Henderson C; Hadlow B; Molloy K; Doab A; Tillakeratne S; Pepolim L; Harrod ME; Dore GJ; Read P
    Int J Drug Policy; 2023 Apr; 114():103982. PubMed ID: 36863287
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
    Kåberg M; Hammarberg A; Lidman C; Weiland O
    Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence and molecular epidemiology of hepatitis C virus reinfection in prisons in Catalonia, Spain (Re-HCV study).
    Saludes V; Bordoy AE; Yela E; Turú E; Not A; López-Corbeto E; Egea-Cortés L; González-Candelas F; Casabona J; ; Marco A; Martró E
    Sci Rep; 2023 Sep; 13(1):16012. PubMed ID: 37749145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determining the frequency and characteristics of Hepatitis C reinfections in North East England.
    Askar S; Jelley R; McQue K; Allsop C; McCullough F; Miller C; Taha Y; Masson S; McPherson S
    J Viral Hepat; 2022 Aug; 29(8):685-690. PubMed ID: 35643915
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis C reinfection in former and active injecting drug users in Belgium.
    Busschots D; Bielen R; Koc ÖM; Heyens L; Verrando R; de Galocsy C; Van Steenkiste C; Nevens F; Midgard H; Dalgard O; Robaeys G
    Harm Reduct J; 2021 Oct; 18(1):102. PubMed ID: 34641896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    Not A; Saludes V; Gálvez M; Miralpeix A; Bordoy AE; González N; González-Gómez S; Muntané L; Reyes-Urueña J; Majó X; Colom J; Forns X; Lens S; Martró E
    J Med Virol; 2023 Feb; 95(2):e28544. PubMed ID: 36727653
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy.
    Iversen J; Dore GJ; Starr M; Catlett B; Cunningham P; Geddes L; Maher L
    Int J Drug Policy; 2020 Sep; 83():102837. PubMed ID: 32645585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatitis C virus treatment in people who inject drugs (PWID) in Bangladesh.
    Rahman M; Janjua NZ; Shafiq TKI; Chowdhury EI; Sarker MS; Khan SI; Reza M; Faruque MO; Kabir A; Anis AH; Azim T
    Int J Drug Policy; 2019 Dec; 74():69-75. PubMed ID: 31542689
    [TBL] [Abstract][Full Text] [Related]  

  • 37. M
    Martel-Laferrière V; Feaster DJ; Metsch LR; Schackman BR; Loignon C; Nosyk B; Tookes H; Behrends CN; Arruda N; Adigun O; Goyer ME; Kolber MA; Mary JF; Rodriguez AE; Yanez IG; Pan Y; Khemiri R; Gooden L; Sako A; Bruneau J
    Trials; 2022 Apr; 23(1):341. PubMed ID: 35461260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implementing and scaling up HCV treatment services for people who inject drugs and other high risk groups in Ukraine: An evaluation of programmatic and treatment outcomes.
    Mazhnaya A; Meteliuk A; Barnard T; Zelenev A; Filippovych S; Altice FL
    Int J Drug Policy; 2017 Sep; 47():187-195. PubMed ID: 28811159
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High Rate of Hepatitis C Virus Reinfection Among Recently Injecting Drug Users: Results From the TraP Hep C Program-A Prospective Nationwide, Population-Based Study.
    Johannesson JM; Fridriksdottir RH; Löve TJ; Runarsdottir V; Hansdóttir I; Löve A; Thordardottir M; Hernandez UB; Olafsson S; Gottfredsson M;
    Clin Infect Dis; 2022 Nov; 75(10):1732-1739. PubMed ID: 35438144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hepatitis C Virus Reinfection Among People Who Inject Drugs: Long-Term Follow-Up of the HERO Study.
    Litwin AH; Tsui JI; Heo M; Mehta SH; Taylor LE; Lum PJ; Feinberg J; Kim AY; Norton BL; Pericot-Valverde I; Arnsten J; Meissner P; Karasz A; McKee MD; Ward JW; Johnson N; Agyemang L; Stein ES; Thomas A; Borsuk C; Blalock KL; Wilkinson S; Wagner K; Carty J; Murray-Krezan C; Anderson J; Jacobsohn V; Luetkemeyer AF; Falade-Nwulia O; Groome M; Davies S; Costello K; Page K;
    JAMA Netw Open; 2024 Aug; 7(8):e2430024. PubMed ID: 39186268
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.